Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.
Author(s): Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G, European/Canadian Glatiramer Acetate Study Group
Affiliation(s): The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA. Jerry.S.Wolinsky@uth.tmc.edu
Publication date & source: 2002-10-22, Neurology., 59(8):1284-6.
Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial; Validation Studies
All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.
|